Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
Schneeweiss A, Lauschner I, Ruiz A, Guerrero A, Sánchez-Rovira P, Seguí MA, Goerke K, Wolf M, Manikhas AG, Wacker J, Marmé F, Lichter P, Sinn HP, Sohn C, Mansouri K, Bauknecht T, Hahn M. Schneeweiss A, et al. Among authors: marme f. Clin Breast Cancer. 2007 Apr;7(7):555-8. doi: 10.3816/CBC.2007.n.011. Clin Breast Cancer. 2007. PMID: 17509164 Clinical Trial.
Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk.
Yang R, Dick M, Marme F, Schneeweiss A, Langheinz A, Hemminki K, Sutter C, Bugert P, Wappenschmidt B, Varon R, Schott S, Weber BH, Niederacher D, Arnold N, Meindl A, Bartram CR, Schmutzler RK, Müller H, Arndt V, Brenner H, Sohn C, Burwinkel B. Yang R, et al. Among authors: marme f. Breast Cancer Res Treat. 2011 Jun;127(2):549-54. doi: 10.1007/s10549-010-1244-x. Epub 2010 Nov 3. Breast Cancer Res Treat. 2011. PMID: 21046227
Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients.
Domschke C, Schuetz F, Ge Y, Rom J, Zorn M, Sinn HP, Marmé F, Schott S, Heil J, Scharf A, Sohn C, Schneeweiss A, Beckhove P. Domschke C, et al. Among authors: marme f. Cancer Immunol Immunother. 2011 Mar;60(3):401-11. doi: 10.1007/s00262-010-0956-4. Epub 2010 Dec 14. Cancer Immunol Immunother. 2011. PMID: 21161218 Free PMC article.
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium.
Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, Apicella C, Smith LD, Hammet F, Southey MC, Van 't Veer LJ, de Groot R, Smit VT, Fasching PA, Beckmann MW, Jud S, Ekici AB, Hartmann A, Hein A, Schulz-Wendtland R, Burwinkel B, Marme F, Schneeweiss A, Sinn HP, Sohn C, Tchatchou S, Bojesen SE, Nordestgaard BG, Flyger H, Ørsted DD, Kaur-Knudsen D, Milne RL, Pérez JI, Zamora P, Rodríguez PM, Benítez J, Brauch H, Justenhoven C, Ko YD; Genica Network; Hamann U, Fischer HP, Brüning T, Pesch B, Chang-Claude J, Wang-Gohrke S, Bremer M, Karstens JH, Hillemanns P, Dörk T, Nevanlinna HA, Heikkinen T, Heikkilä P, Blomqvist C, Aittomäki K, Aaltonen K, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Kauppinen JM, Kataja V, Auvinen P, Eskelinen M, Soini Y, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Holland H; kConFab; AOCS; Lambrechts D, Claes B, Vandorpe T, Neven P, Wildiers H, Flesch-Janys D, Hein R, Löning T, Kosel M, Fredericksen ZS, Wang X, Giles GG, Baglietto L, Severi G, McLean C, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Alnæs GG, Kristensen V, Børresen-Dale AL, Hunter DJ, Hankinson SE, Andrulis IL, Mulligan AM, O'Malley FP, Devilee P, Huijts PE, Tolle… See abstract for full author list ➔ Broeks A, et al. Among authors: marme f. Hum Mol Genet. 2011 Aug 15;20(16):3289-303. doi: 10.1093/hmg/ddr228. Epub 2011 May 19. Hum Mol Genet. 2011. PMID: 21596841 Free PMC article.
Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer.
Milne RL, Goode EL, García-Closas M, Couch FJ, Severi G, Hein R, Fredericksen Z, Malats N, Zamora MP, Arias Pérez JI, Benítez J, Dörk T, Schürmann P, Karstens JH, Hillemanns P, Cox A, Brock IW, Elliot G, Cross SS, Seal S, Turnbull C, Renwick A, Rahman N, Shen CY, Yu JC, Huang CS, Hou MF, Nordestgaard BG, Bojesen SE, Lanng C, Grenaker Alnæs G, Kristensen V, Børrensen-Dale AL, Hopper JL, Dite GS, Apicella C, Southey MC, Lambrechts D, Yesilyurt BT, Floris G, Leunen K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Chang-Claude J, Wang-Gohrke S, Radice P, Peterlongo P, Manoukian S, Barile M, Giles GG, Baglietto L, John EM, Miron A, Chanock SJ, Lissowska J, Sherman ME, Figueroa JD, Bogdanova NV, Antonenkova NN, Zalutsky IV, Rogov YI, Fasching PA, Bayer CM, Ekici AB, Beckmann MW, Brenner H, Müller H, Arndt V, Stegmaier C, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Meindl A, Heil J, Bartram CR, Schmutzler RK, Thomas GD, Hoover RN, Fletcher O, Gibson LJ, dos Santos Silva I, Peto J, Nickels S, Flesch-Janys D, Anton-Culver H, Ziogas A, Sawyer E, Tomlinson I, Kerin M, Miller N, Schmidt MK, Broeks A, Van 't Veer LJ, Tollenaar RA, Pharoah … See abstract for full author list ➔ Milne RL, et al. Among authors: marme f. Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2222-31. doi: 10.1158/1055-9965.EPI-11-0569. Epub 2011 Jul 27. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21795498 Free PMC article.
The rs12975333 variant in the miR-125a and breast cancer risk in Germany, Italy, Australia and Spain.
Peterlongo P, Caleca L, Cattaneo E, Ravagnani F, Bianchi T, Galastri L, Bernard L, Ficarazzi F, Dall'olio V, Marme F, Langheinz A, Sohn C, Burwinkel B, Giles GG, Baglietto L, Severi G, Odefrey FA, Southey MC, Osorio A, Fernández F, Alonso MR, Benítez J, Barile M, Peissel B, Manoukian S, Radice P. Peterlongo P, et al. Among authors: marme f. J Med Genet. 2011 Oct;48(10):703-4. doi: 10.1136/jmedgenet-2011-100103. J Med Genet. 2011. PMID: 21931172 No abstract available.
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.
Marmé F, Werft W, Walter A, Keller S, Wang X, Benner A, Burwinkel B, Sinn P, Hug S, Sohn C, Bretz N, Moldenhauer G, Rupp C, Rupp AK, Biakhov MY, Bottini A, Friedrichs K, Khailenko VA, Manikhas GM, Ruiz A, Sánchez-Rovira P, Santoro A, Segui MA, Villena C, Lichter P, Kristiansen G, Altevogt P, Schneeweiss A. Marmé F, et al. Breast Cancer Res Treat. 2012 Apr;132(3):819-31. doi: 10.1007/s10549-011-1759-9. Epub 2011 Sep 30. Breast Cancer Res Treat. 2012. PMID: 21960110 Clinical Trial.
Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.
Marmé F, Hielscher T, Hug S, Bondong S, Zeillinger R, Castillo-Tong DC, Sehouli J, Braicu I, Vergote I, Isabella C, Mahner S, Ferschke I, Rom J, Sohn C, Schneeweiss A, Altevogt P. Marmé F, et al. Int J Cancer. 2012 Aug 15;131(4):E586-91. doi: 10.1002/ijc.27329. Epub 2012 Jan 31. Int J Cancer. 2012. PMID: 22034009
257 results